V
Vivacelle Bio
Pre-clinical stage life science company focused on bringing to market a new paradigm in resuscitation fluids
About Vivacelle Bio
Vivacelle Bio, Inc. is a developmental stage biotechnology company focused on creating innovative products utilizing nanoparticle technology. The company's primary product, VBI 1, is a colloid non-blood volume expander designed to treat hypovolemia, a condition characterized by inadequate fluid volume in blood vessels. Hypovolemia can result from acute blood loss due to trauma, surgery, shock, sepsis, severe diarrhea, and burns, leading to cellular injury and death if untreated. VBI 1 has shown to be two to three times more effective and safer than standard treatments in animal studies. The FDA granted clearance for a phase IIa clinical trial of VBI 1 on February 1, 2019.
Vivacelle Bio operates in the biotechnology and healthcare market, primarily targeting medical institutions and healthcare providers dealing with emergency and critical care situations. The company's business model revolves around the development and commercialization of its proprietary nanoparticle-based treatments. Revenue generation is expected through the successful clinical trials, regulatory approvals, and subsequent sales and licensing of its products.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2024 | $20M | $80M | 2Flo Ventures (Chicago) | ↗ |
| SERIES AEquity / VC | Aug 2018 | $1.2M | $4.8M | Undisclosed | — |
Growth signals
Latest recorded traffic for Vivacelle Bio is 420 monthly website visits, down 48.8% over the last three months. Vivacelle Bio's team grew 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vivacelle Bio in the Chicago ecosystem
The Vivacelle Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
2Flo Ventures (Chicago)
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vivacelle Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vivacelle Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










